Dr. Falk Pharma GmbH

Industry / private company


Location: Freiburg, Germany (DE) DE

ISNI: 0000000404935305

ROR: https://ror.org/05sh9vm75

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease (2024) Dotsenko V, Tewes B, Hils M, Pasternack R, Isola J, Taavela J, Popp A, et al. Journal article Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial (2022) Kruis W, Siegmund B, Lesniakowski K, Simanenkov V, Khimion L, Sobon M, Delmans G, et al. Journal article Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6-week open-label trial of the EOS-2 Programme (2022) Miehlke S, Schlag C, Lucendo AJ, Biedermann L, Vaquero CS, Schmoecker C, Hayat J, et al. Journal article A randomized trial of a transglutaminase 2 inhibitor for celiac disease (2021) Schuppan D, Mäki M, Lundin KE, Isola J, Friesing-Sosnik T, Taavela J, Popp A, et al. Journal article Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis (2019) Kruis W, Neshta V, Pesegova M, Alekseeva O, Andreev P, Datsenko O, Levchenko O, et al. Journal article norUrsodeoxycholic acid (norUDCA) improves non-alcoholic fatty liver disease (NAFLD): Results from a randomized placebo-controlled, double-blind phase IIa study (2017) Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G, Hofmann WP, et al. Conference contribution